R&D success is in the cloud

17 October 2014

Global pharma companies have formed a cloud coalition which aims to speed up the drug development process.

Accenture has launched the Accenture Life Sciences Cloud for R&D, which aims to speed up clinical development, improve patient outcomes and create greater R&D efficiency through a new single analytics platform that brings together multiple internal and external data sources across clinical, safety, regulatory and operational functions.

It has also formed a Life Sciences Cloud Coalition, which includes Eisai, Merck and Pfizer. The aim of this group is to collaborate on the Life Sciences Cloud and digitally enable the R&D function, speed up the drug development process while improving quality and cost for the industry.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK